The US Food and Drug Administration has approved the use of a novel painkiller as an effective treatment for short-term ...

The trials compared a pharmacologic analgesic versus an alternative analgesic or placebo. Twenty-five trials enrolled participants with musculoskeletal pain, six with otorhinolaryngologic pain ...

African American patients are less likely than White patients to receive comprehensive pain treatment post- noncardiac ...

Dr. Sanjay Gupta said Tuesday that the approval of a new non-opioid pain medication is “a pretty big deal.” “This is a pretty ...

Today, the U.S. Food and Drug Administration (FDA) gave its approval to Vertex Pharmaceuticals' (NASDAQ: NASDAQ:VRTX) ...

Taiwanese pharmaceutical company Xgene Pharmaceutical announced that its non-opioid analgesic drug XG005 has reduced acute pain in patients after surgery in a Phase IIb study[MV1] . The placebo ...

The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first-in-class ...

Am J Health Syst Pharm. 2007;64(11):1148-1152. Health care organizations around the nation have been working to reduce the use of meperidine as a first-line agent for pain management. Despite the ...

Suzetrigine selectively inhibits the NaV1.8 pain-signaling pathway in the peripheral nervous system and provides effective ...

FDA Approves Non-Opioid Treatment for Moderate to Severe Acute Pain as Agency Continues to Take Steps to Support New ...

The FDA has approved Journavx 50 mg oral tablets for the treatment of moderate to severe acute pain in adults, according to a ...